UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000035036
Receipt No. R000039948
Scientific Title A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract: a randomized double-blind, parallel-group, placebo-controlled study
Date of disclosure of the study information 2019/11/27
Last modified on 2021/05/25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract: a randomized double-blind, parallel-group, placebo-controlled study
Acronym A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract
Scientific Title A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract: a randomized double-blind, parallel-group, placebo-controlled study
Scientific Title:Acronym A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract
Region
Japan

Condition
Condition Healthy Japanese subjects
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the effects of the test food on urination issues
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes International Prostate Symptom Score (IPSS)
*Calculate the change between screening (before consumption) and 8 weeks after consuming
Key secondary outcomes 1. IPSS

2. Overactive Bladder Symptom Score (OABSS)

3. Original questionnaires (Likert scale)

4. Ultrasonography of the post-void residual volume of urine

*1,2,3 Assess these at screening (before consumption) and 4 and 8 weeks after consuming
*4 Assess at screening (before consumption) and 8 weeks after consuming

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification NO
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Duration: 8 weeks
Test material: Capsule containing saw palmetto extract
Dose: Take one capsule per day
Administration: Swallow a capsule before sleeping with water (about 200 mL) and no chewing
Interventions/Control_2 Duration: 8 weeks
Test material: Placebo capsule
Dose: Take one capsule per day
Administration: Swallow a capsule before sleeping with water (about 200 mL) and no chewing
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit

Not applicable
Gender Male
Key inclusion criteria 1. Healthy Japanese men who are 40 or more years old

2. Those who have nocturia at least twice

3. Those who are considered as appropriate for the study by the principal investigator

4. Those whose high-sensitivity PSA level is less than 3.0 ng/mL (40-64 years old), less than 3.5 ng/mL (65-70 years old), or less than 4.0 ng/mL (more than 70 years old) at screening (before consumption)

5. Those who have 8-19 points in the IPSS at screening (before consumption) and do not need the treatment

6. Select those who have relatively high score in the IPSS
Key exclusion criteria 1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction

2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases

4. Those who need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, overactive bladder, and urolithiasis

5. Those who use or take "Foods for Specified Health Uses" and "Foods with Function Claims" in daily

6. Currently taking medications (including herbal medicines) and dietary supplements

7. Those who are an allergic reaction to medications and/or the test food related products

8. Those who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial

9. Other considerations as ineligibility to participate in the study based on the evaluation of the principal physician
Target sample size 40

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kazuo YAMAMOTO
Organization ORTHOMEDICO Inc.
Division name CEO
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL 03-3818-0610
Email kazu@orthomedico.jp

Public contact
Name of contact person
1st name
Middle name
Last name Naoko SUZUKI
Organization ORTHOMEDICO Inc.
Division name R&D Department
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL 03-3818-0610
Homepage URL
Email nao@orthomedico.jp

Sponsor
Institute ORTHOMEDICO Inc.
Institute
Department

Funding Source
Organization BGG Japan Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Medical Corporation Seishinkai, Takara Clinic

Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

Other administrative information
Date of disclosure of the study information
2019 Year 11 Month 27 Day

Related information
URL releasing protocol Unpublished
Publication of results Published

Result
URL related to results and publications http://www.pieronline.jp/content/article/0386-3603/48030/429
Number of participants that the trial has enrolled 44
Results Sekikawa T, Kizawa Y, Li Y, Takara T. Verification study on the effects of saw palmetto fruit extract on urination issues: A randomized double-blind, parallel-group, placebo-controlled study. Jpn Pharmacol Ther. 2020; 48(3): 429-440
Results date posted
2021 Year 05 Month 25 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
2020 Year 03 Month 30 Day
Baseline Characteristics Refer to the paper
Participant flow Refer to the paper
Adverse events Refer to the paper
Outcome measures Refer to the paper
Plan to share IPD Undecided
IPD sharing Plan description To require consultation among related companies

Progress
Recruitment status Completed
Date of protocol fixation
2018 Year 11 Month 12 Day
Date of IRB
2018 Year 11 Month 12 Day
Anticipated trial start date
2018 Year 11 Month 28 Day
Last follow-up date
2019 Year 04 Month 27 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 11 Month 27 Day
Last modified on
2021 Year 05 Month 25 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039948

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.